	US 12,390,516 B2
	Vaccines against tick-borne diseases
Roman R. Ganta, Manhattan, KS (US)
Assigned to Kansas State University Research Foundation, Manhattan, KS (US)
Appl. No. 16/631,964
Filed by Kansas State University Research Foundation, Manhattan, KS (US)
PCT Filed Jul. 17, 2018, PCT No. PCT/US2018/042496 § 371(c)(1), (2) Date Jan. 17, 2020, PCT Pub. No. WO2019/027670, PCT Pub. Date Feb. 7, 2019.
Claims priority of provisional application 62/533,550, filed on Jul. 31, 2017.
Prior Publication US 2020/0164055 A1, May 28, 2020
Int. Cl. A61K 39/02 (2006.01); A61K 39/00 (2006.01); A61P 31/04 (2006.01)

CPC A61K 39/0233 (2013.01) [A61P 31/04 (2018.01); A61K 2039/521 (2013.01); A61K 2039/54 (2013.01); A61K 2039/542 (2013.01); A61K 2039/552 (2013.01); A61K 2039/55566 (2013.01)]

5 Claims

1. An immunogenic composition comprising:

a first inactivated whole cell bacteria selected from the group consisting of Rickettsia rickettsii, Ehrlichia chaffeensis, Anaplasma marginale, Anaplasma phagocytophilum, and any combination thereof; and

an adjuvant, selected from the group consisting of Quil A, aluminum hydroxide, montanide, and any combination thereof.